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Abstract. The amyloid- protein precursor/presenilin 1 (APP/PS1) mouse model of Alzheimer’s disease (AD) has provided
robust neuropathological hallmarks of familial AD-like pattern. AD is a neurodegenerative process that causes severe cognitive
impairment; it is characterized by the accumulation of amyloid- (A) and hyperphosphorylated tau forms and by oxidative and
inflammatory processes in brain. Currently, efforts are made to understand biochemical pathways because there is no effective
therapy for AD. Resveratrol is a polyphenol that induces expression and activation of several neuroprotective pathways involving
Sirtuin1 and AMPK. The objective of this work was to assess the effect of oral resveratrol administration on APP/PS1 mice.
Long-term resveratrol treatment significantly prevented memory loss as measured by the object recognition test. Moreover,
resveratrol reduced the amyloid burden and increased mitochondrial complex IV protein levels in mouse brain. These protective
effects of resveratrol were mainly mediated by increased activation of Sirtuin 1 and AMPK pathways in mice. However, an
increase has been observed in IL1 and TNF gene expression, indicating that resveratrol promoted changes in inflammatory
processes, although no changes were detected in other key actors of the oxidative stress pathway. Taken together, our findings
suggest that resveratrol is able to reduce the harmful process that occurs in APP/PS1 mouse hippocampus, preventing memory
loss.
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INTRODUCTION
A central issue in cognitive neuroscience of research
on aging is pinpointing precise neural mechanisms
that determine cognitive outcome in late adulthood,
as well as identifying early markers of neurodegen-
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eration and preventive strategies to impede cognitive
impairment in aging. Alzheimer’s disease (AD) is the
most prevalent neurodegenerative disorder associated
with age and characterized by senile plaques and neu-
rofibrillary tangles. Senile plaques are formed by the
accumulation of amyloid- (A)1–40 and A1–42 pep-
tides, which result from the sequential cleavage of
amyloid- protein precursor (APP) by -secretase
(BACE) and -secretase. The production of A pep-
tides is prevented by alternative cleavage of APP by
-secretase followed by -secretase. Donmez et al.
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[1] have reported that production of A and plaques
in the 3xTg-AD transgenic mouse model of AD is
reduced by the overexpression of Sirtuin 1 (SIRT1) and
is increased by knocking out SIRT1 in brain. SIRT1
directly activates transcription of the gene encoding
-secretase, the ADAM10 gene. Additionally, SIRT1
deacetylates and coactivates the Retinoic acid receptor
, a known regulator of ADAM10 transcription.
It is noteworthy that in AD, mitochondrial func-
tion is affected. Reduction of mitochondrial complex
IV (MCIV) activity [2, 3] and increased reactive
oxygen species production [4, 5] was reported else-
where. Accumulation of mitochondrial DNA changes
might increase reactive oxygen species production
and reduce mitochondrial adenine triphosphate (ATP)
in an age-dependent manner. Increases of somatic
mitochondrial DNA in aging might contribute to AD
development [6].
An early-onset form of AD, familial AD (defined
for individuals <65 years of age), accounts for 5% of
all cases and is directly linked with highly penetrant
autosomal dominant mutations in one of three different
genes: the presenilin 1 (PS1) gene; the PS2 gene, or the
APP gene.
Resveratrol, a natural polyphenolic compound
found in grapes and red wine, increases metabolic rate,
insulin sensitivity, mitochondrial biogenesis, and phys-
ical endurance, and also reduces fat accumulation in
mice and, at the brain level, is postulated as an option
to prevent AD [7–9]. Although it is thought that resver-
atrol targets SIRT1, this remains controversial because
resveratrol also activates 5-Adenosine monophosphate
(AMP)-activated protein kinase (AMPK), which also
regulates insulin sensitivity and mitochondrial biogen-
esis. Um et al. [10] demonstrated that the metabolic
effects of resveratrol are dependent on AMPK using
knockout mice. In addition, resveratrol, during food
deprivation (caloric restriction), causes an increase
in the cellular AMP/ATP ratio, resulting in the
activation of AMPK, which initiates a signaling pro-
cess that recruits mediators of oxidative metabolism
and mitochondrial biogenesis including PGC1-,
the peroxisome proliferator-activated receptor-gamma
(PPAR-δ), and others [11].
Double-transgenic APP/PS1 mice express a
chimeric mouse/human APP bearing the Swedish
mutation (Mo/Hu APP695swe) and a mutant human
PS1-dE9, both causative of familial AD. Transgenic
mice show senile plaques in cortical and hippocam-
pal areas starting at 4 months [12] and impaired
memory and learning performance between 6 and 15
months [13–15]. However, these mice have no alter-
ations in motor function or anxiety-related behavior
[16]. Moreover, these animals have increased BACE
activity [17], decreased ADAM10 expression [18], and
decreased synaptosomal synaptophysin [19]. In refer-
ence to inflammatory markers APP/PS1 mice present
elevaled levels of IL-1 [20] and TNF [21].
The aim of this work was to elucidate the inter-
plays between the amyloidogenic pathway, SIRT1 and
AMPK signaling, and resveratrol as a preventative
agent in the mouse familial AD model APP/PS1. The
generation of this knowledge would afford us new clues
to confront neurodegenerative disorders with abnormal
APP processing, such as familial AD, and to help in
preventing the processes linked with this illness.
METHODS
Animals and resveratrol feeding
All animal protocols were conducted and approved
by the Ethic Committee for Animal Use from the Uni-
versity of Barcelona in accordance with the Generalitat
de Catalunya guidelines for the Care and Use of Lab-
oratory Animals. All efforts were made to minimize
animal numbers and distress.
APPswe/PS1dE9 male mice (2 months of age)
that were treated and age-matched control littermates
were both fed with mouse chow (Harlam Diet) con-
taining 1% resveratrol [22] or the same chow without
resveratrol (n = 10 in each group) for 10 months.
Daily resveratrol consumption was calculated to be
4 mg/kg/day (mean of food intake of 4 g/animal/day).
Novel object recognition test (NORT)
Changes in cognition were tested with an object-
recognition task as described elsewhere [23]. Animals
were placed in a 90◦, two-arm, 25-cm-long, 20-cm-
high, and 5-cm-wide black maze. Light intensity in
the middle of the field was 30 lux. The objects to be
discriminated were made of plastic (object A, 5.25 cm
in height, and object B, 4.75 cm in height). For the first
3 days, the mice were individually acclimatized to the
apparatus for 10 min. On day 4, the animals were sub-
mitted to a 10-min acquisition trial (first trial), during
which they were placed in the maze in the presence
of two identical novel objects (A+A or B+B), which
were localized at the end of each arm. A 10-min reten-
tion trial (second trial) occurred 2 h later. During this
second trial, objects A and B were placed in the maze,
and the time that the animal explored the new object
(tn) and the old object (to) were recorded. A Discrim-
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ination index (DI) was defined as (tn–to)/(tn+to). In
order to avoid object preference biases, objects A and
B were counterbalanced so that one half of the ani-
mals in each experimental group were first exposed to
object A and then to object B, whereas the remaining
one half first saw object B and then object A. The maze
and the objects were cleaned with 96◦ ethanol between
experiments to eliminate olfactory cues.
Brain processing
Animals were anesthetized with 80 mg/kg of sodium
pentobarbital and intracardially perfused with saline
serum. Afterward, brains were dissected and separated
sagitally into two hemispheres: one for histological
staining, and the other, for protein and RNA extraction.
Hemispheres for histological staining were frozen by
immersion in isopentane, chilled on dry ice, and stored
at –80◦C until sectioning. Thereafter, the frozen brains
were embedded in Optimal cutting temperature (OCT)
cryostat-embedding compound (Tissue-Tek; Torrance,
CA, USA), cut into 20-m-thick sections on a cryostat
(Leyca Microsystems, Germany) at –18◦C, and placed
on slides. Slides containing brain sections were fixed
with acetone for 10 min at 4◦C, allowed to dry at room
temperature, and then frozen at –20◦C until further
staining. The remaining hemispheres were dissected
and stored at –80◦C until protein or RNA extraction.
Thioﬂavin S staining
Slides were allowed to defrost at room tempera-
ture and then were rehydrated with Phosphate-buffered
saline (PBS) for 5 min. Later, the brain sections were
incubated with 0.3% Thioflavin S (Sigma-Aldrich) for
20 min at room temperature in the dark. Subsequently,
these were submitted to washes in 3-min series, specif-
ically with 80% ethanol (2 washes), 90% ethanol (1
wash), and 3 washes with PBS. Finally, the slides were
mounted using Fluoromount (EMS), allowed to dry
overnight at room temperature in the dark, and stored
at 4◦C. Image acquisition was performed with an epi-
fluorescence microscope (BX41; Olympus, Germany).
For plaque quantification, similar and comparable his-
tological areas were selected, focusing on having the
hippocampus and the whole cortical area positioned
adjacently.
Protein extraction
Brains were micronized by freezing with liquid
nitrogen and grinding with a mortar. For total pro-
tein extraction, lysis buffer (50 mM Tris-HCl, 150 mM
NaCl, 5 mM EDTA, 1% Triton X-100, pH 7.4), EDTA-
free Protease inhibitor cocktail (Roche, Mannheim,
Germany), and Phosphatase inhibitor cocktail 1
(Sigma-Aldrich, St. Louis, MO, USA) were added to
micronized tissue and left on ice for 30 min. Then, the
samples were centrifuged at 10,000× g for 10 min and
a supernatant with total protein content was collected.
All of the protein extraction steps were carried out
at 4◦C. Protein concentration was determined by the
Bradford protein assay.
Western blot
For western blot analysis, 20g of protein were
denatured at 95◦C for 5 min in sample buffer (0.5 M
Tris-HCl, pH 6.8, 10% glycerol, 2% Sodium dodecyl
sulfate [SDS], 5% -mercaptoethanol, 0.05% bro-
mophenol blue), separated by Sodium dodecyl sulfate-
Polyacrylamide gel electrophoresis (SDS-PAGE) onto
8–12% polyacrylamide gels and transferred onto
Immobilon polyvinylidene difluoride membranes
(Millipore, Billerica, MA, USA). The membranes
were incubated overnight at 4◦C with the following
primary antibodies: anti--actin (Sigma; 1:10,000);
anti-Sirt1 (Abcam, 1:1,000); anti-p53 (Abcam, 1:500);
anti-acetyl p53 (L382) (Millipore, 1:500); anti-AMPK
(Cell Signaling, 1:1,000); anti-pAMPK (Cell Signal-
ing, 1:1,000); OXPHOS cocktail and porin (1:500;
MitoSciences); catalase (1:2,000; Calbiochem), and
superoxide dismutase (SOD) (1:3000; Calbiochem)
diluted with Tris-buffered saline containing 0.1%
Tween 20 (TBS-T) and 5% Bovine serum albumin
(BSA). Membranes were then washed and incubated
with secondary antibodies and diluted with TBS-T for
1 h at room temperature. Protein bands were visual-
ized using a chemiluminescent horseradish peroxidase
substrate (Millipore) and ChemiDoc XRS + (Bio-
rad). Band intensities were quantified by densitometric
analysis using Image Lab software and values were
normalized to -actin.
RNA extraction and gene expression determination
Total RNA isolation was carried out by means of Tri-
zol reagent following the manufacturer’s instructions.
RNA content in the samples was measured at 260 nm,
and the purity of the samples was determined by the
A260/280 ratio in a NanoDrop ND-1000 (Thermo Sci-
entific). Samples were also tested in a Bioanalyzer
2100B (Agilent Technologies) to determine the RNA
integrity number.
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Reverse transcription-polymerase chain reaction
(RT-PCR) was performed as follows: 2g of mes-
senger RNA (mRNA) was reverse-transcribed using
the High Capacity cDNA Reverse Transcription
kit (Applied Biosystems). Then, qPCR was per-
formed using TaqMan gene expression assays (Applied
Biosystems), doing triplicates for each gene and cDNA
sample in 96-well optical plates. The TaqMan probes
used were Interleukin-1 (Il1b) (Mm00434228 m1),
Interleukin-6 (Il6) (Mm00446190 m1), Tumor necro-
sis factor (Tnf) (Mm00443260 g1), Nuclear factor ery-
throid 2-related factor 2 (Nfe2l2) (Mm00477784 m1),
Heme oxygenase-1 (Hmox) (Mm00516005 m1), and
Jun (Jun) (Mm00495062), with TATA-binding pro-
tein (Tbp) (Mm00446971 m1) as housekeeping. For
each 20l of TaqMan reaction, 9l cDNA (25 ng)
was mixed with 1L 20x probe of TaqMan Gene
Expression Assays and 10l of 2x TaqMan Univer-
sal PCR Master Mix. The reactions were carried out
using the following parameters: 50◦C for 2 min; 95◦C
for 10 min, 40 cycles at 95◦C for 15 s, and at 60◦C
for 1 min using the StepOnePlus Real-Time PCR Sys-
tem (Applied Biosystems). Finally, all TaqMan PCR
data were normalized to TBP using the delta-delta Ct
method.
Statistical analysis
Results were analyzed statistically by GraphPad
PRISM (GraphPad Software, Inc.) software. Data
are presented as mean ± Standard error of the mean
(SEM), and means were compared with two-tailed,
unpaired Student t-test. In the Object recognition
test (ORT), a one-sample t-test was used to examine
whether single columns were different from zero. Sta-
tistical significance was reached when p values were
<0.05. All the experiments and its statistics were con-
ducted with 7 to 10 animals for each experimental
group.
RESULTS
Resveratrol ameliorated short-term memory in
AβPP/PS1 mice
To date, it has been found that transgenic mice that
overexpress APP/PS1 show loss of memory [13–15].
ORT demonstrated that at 12 months, APP/PS1
mice fed with resveratrol chow exhibited significantly
improved memory capabilities (Fig. 1A) in comparison
to APP/PS1 control mice.
Fig. 1. A) Object recognition test analysis for APP/PS con-
trol and resveratrol-fed mice. Bars represent discrimination index,
mean ± Standard error of the mean (SEM). One sample t-test
**p < 0.01 from zero. Student t-test versus control; #p < 0.05. B)
Western blot analysis for synaptophysin in APP/PS1 control and
resveratrol-fed mice. Results are represented as mean ± SEM. Stu-
dent t-test versus control; *p < 0.05.
The previously mentioned beneficial effects of
resveratrol were supported by an increase in synap-
tophysin, a presynaptic protein that reflects an
improvement in synaptic activity in resveratrol-fed
mice (Fig. 1B).
Resveratrol treatment reduced plaque pathology
but did not alter AβPP and its carboxy terminal
fragments (CTF) in AβPP/PS1 mice
To test the effect of resveratrol on amyloid plaque
pathology, thioflavin S staining was used. Resvera-
trol markedly reduced thioflavin S-positive compact
plaques compared with control mice (Fig. 2). Quan-
tification of plaques revealed a significant reduction in
plaque counts and plaque burden in hippocampus and
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Fig. 2. A) Thioflavin S staining of A plaques in mouse brains. Representative images of histopathological brain state of APP/PS1 control and
resveratrol-fed mice. White arrows are representative indicators of the presence of A plaques in the studied areas, cortex (C), and hippocampus
(H). Bar chart showing quantification of the number of amyloid plaques in the cerebral cortex (B) and hippocampus (C) of APP/PS1 control
and resveratrol-treated animals. For quantification parameters, see Materials and Methods. Bars represent mean ± Standard error of the mean
(SEM). Student t-test *p < 0.05; **p < 0.01 versus control.
medial cortex of resveratrol-fed mice compared with
controls (Fig. 2A-C).
To investigate the mechanism responsible for
the resveratrol-induced reduction in plaque counts,
enzymes that mediate APP cleavage were deter-
mined. We found no changes in PS1, but a significant
reduction in BACE and ADAM 10 protein levels were
observed (Fig. 3A–C).
Moreover, full-length APP and APP cleavage
products  CTF (C99) and  CTF (C83) levels were
determined by western blot using APP G369 anti-
body (against the APP cytoplasmic tail). Resveratrol
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Fig. 3. Levels of presenilin 1 (PS1) (A), ADAM10 (B), -secretase (BACE) (C), APP (D), C99 (E), and C83 (F) in APP/PS1 control and
resveratrol-fed mice. Bars represent mean ± Standard error of the mean (SEM). Student t-test: *p < 0.05; **p < 0.01 versus control.
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Fig. 4. Western blot analysis for Sirtuin 1 (SIRT1) (A), acetylated-p53 (B), phospho-5-Adenosine monophosphate (AMP)-activated pro-
tein kinase (p-AMPK) (C), mitochondrial complex IV (MCIV) (D), and serine–threonine kinase liver kinase B (LKB) (E). Bars represent
mean ± Standard error of the mean (SEM); Student t-test: *p < 0.05 versus control.
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Fig. 5. Increases in gene expression for Interleukin-1 (IL1) (A) and tumor necrosis factor (TNF) (B). Western blot analysis for protein levels
of superoxide dismutase (SOD) and catalase (CAT) (C, D). Bars represent mean ± Standard error of the mean (SEM); Student t-test: *p < 0.05
versus control.
did not alter levels of high-molecular-weight APP
(holo APP) (Fig. 3D),  CTF (C99) (Fig. 3E), or 
CTF (C83) (Fig. 3F).
Resveratrol treatment increases the
phospho-AMPK (p-AMPK)/LKB pathway in
AβPP/PS1 although SIRT1 levels are decreased
Because previous studies demonstrated that resver-
atrol activates the nicotinamide adenine dinucleotide
(NAD)-dependent protein deacetylase SIRT1, we
tested whether the SIRT1 protein level was upregulated
in APP/PS1 mice fed with resveratrol. As demon-
strated in Fig. 4, resveratrol treatment did not increase
SIRT1, but a significant diminution in acetyl-p53, one
of the main substrates of SIRT1, was observed (Fig. 4A,
B). Moreover, p-AMPK and also p-LKB were signif-
icantly increased in mice fed resveratrol (Fig. 4C–E),
indicating modulation by this polyphenol on phospho-
rylation, thus on the activity of these two kinases. In
reference to mitochondria and according to stimulation
of AMPK, an increase in MCIV expression, but not
in other complexes, was determined after resveratrol
treatment (Fig. 4D).
Effect of resveratrol treatment on cytokine gene
expression and catalase/superoxide dismutase
(CAT/SOD) protein levels in hippocampus
To test the effect of resveratrol on inflammation
and oxidative stress, different markers for these were
determined. Resveratrol feeding increased Il1b and Tnf
mRNA expression (Fig. 5A, B). In contrast, no changes
were determined in Il6, Nfe2l2, Hmox, and Jun expres-
sion (data not shown). Protein levels of CAT and SOD
were also unchanged (Fig. 5C, D).
DISCUSSION
APP/PS1 mice express a chimeric mouse/human
amyloid- protein precursor (Mo/Hu APP695swe)
and a mutant human presenilin 1 (PS1-dE9) that lead to
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altered APP and PS1 proteins. Both cause A plaques
from 3 months onward, and they increase in number
and distribution with disease progression in paral-
lel with increased levels of brain-soluble A1–42 and
A1–40, but also with a reduced A1–42/1–40 ratio with
age. Amyloid deposition in plaques is accompanied by
altered mitochondria and increased oxidative damage,
post-translational modifications, and the accumulation
of altered proteins at the dystrophic neurites surround-
ing plaques [24]. This model is taken as a familial
AD murine model. Resveratrol has been described
as a natural compound with pleiotropic neuropro-
tective activities, linked with antioxidant properties
and the modification of activity of different enzy-
matic pathways, such as the SIRT1 pathway, AMPK
activation, or cellular protein degradation machinery
[25].
APP/PS1 mice fed with resveratrol showed a
significant decrease in the number and intensity of
amyloid plaques, when were measured by specific S-
thioflavine staining. Reduction in plaque pathology
did not appear to be due to altered APP processing
toward the non-amyloidogenic pathway, because high-
molecular-weight APP (holo APP), C99 (Carboxy
terminal fragment beta, CTF), and C83 (Carboxy ter-
minal fragment alpha, CTF) were unaltered; this is in
agreement with a study conducted by Karuppagounder
and coworkers [26] on Tg19959 fed with resvera-
trol. However, the significant decrease in BACE levels
would ultimately have altered the amyloidogenic path-
way, leading to a reduction in amyloid burden found
in APP/PS1 fed for a lengthy period with resveratrol.
Evidence is compelling that a decrease in proteasome
activity occurs in AD brains [27, 28] and in AD murine
models, including APP/PS1, a familial AD model
[24, 29], and in vitro, resveratrol promotes A clear-
ance by increasing intracellular proteasomal activity
without affecting A- producing enzyme activities (-
secretase and -secretase) [30]. This mechanism on
the proteasomal system exerted by resveratrol could
be synergistic to BACE reduction, explaining the
decrease in plaques observed with resveratrol treat-
ment, albeit than a decrease in ADAM10 was also
determined.
Improvement of short-term memory in these mice
was evaluated by the novel object recognition test
(NORT), a test widely used to evaluate learning and
memory [24, 31]. The brain areas involved in this test
are mainly hippocampus and perirhinal cortex. More-
over, NORT requires no external motivation, reward
or punishment, thus avoiding the anxyogenic role
in cognition impairment, although APP/PS1 mice
do not present anxiety behavior [32, 33]. Synapto-
physin, an integral membrane glycoprotein present in
presynaptic vesicles, was used to quantify synapse
number. In our case, APP/PS1 mice resveratrol fed
increased synaptophysin levels, correlating with short-
term memory improvement and reduction in amyloid
plaques.
Several reports suggest that resveratrol possesses
antioxidant properties [34]; thus, a tantalizing alterna-
tive speculation is that resveratrol-induced reduction
in plaques may be occurring through its effect on the
cellular antioxidant machinery. We measured protein
levels of CAT and SOD, but there were no changes
observed. In relation to the expression of several genes
related with oxidative stress and inflammation, there
were no changes found in the Nfe2l2 and Hmox1 genes,
which are implicated in neuroprotection mechanisms
[35, 36], whereas cytokines linked with inflammation
processes, such as IL1 and TNF, were increased.
In AD, abnormal accumulation of A is thought to
be intimately linked with the immune system [37].
The majority of efforts have been carried out in
order to understand the role of activated astroglia and
microglia, which secrete cytokines that act in favor
of phagocytosis and APP and A peptide clear-
ance, giving rise to the hypothesis that slight increases
in cytokines will be protective by removing A and
reducing the plaque burden in brain. Our results indi-
cate that at this time of treatment, there is no effective
action of resveratrol on the inflammation and oxidative
machinery of APP/PS1 mice; the antioxidant effect
could have occurred at an earlier treatment time, as
described for another AD murine model by Karup-
pagounder and coworkers [26]. However, long-term
resveratrol treatment allows fine control of antioxidant
machinery by increasing IL1 and TNF, leading to a
hormetic process that ultimately yielded a reduction in
plaque number and the beneficial effect on memory, as
we observed clearly in this familal AD mouse model
at a late age. This fact cannot rule out the possibility
that resveratrol exerts an earlier antioxidant effect at
younger ages, acting as a preventive more than as a
curative agent.
In addition, resveratrol has been postulated to have
its beneficial effects on the lifespan, neurodegenera-
tion, and memory improvement by activation of SIRT1
[38, 39]. Because SIRT1 activation is one of the
main targets defined for the pharmacological effects
of resveratrol, the levels of this deacetylase were
determined. Here we observed a diminution in SIRT1
protein levels, but a decrease in acetyl-p53 was deter-
mined concomitantly. These results are in agreement
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with the literature in other transgenic models and in in
vitro experiments where a reduction in plaque pathol-
ogy without increase in sirtuin levels [26] but decrease
in PGC1 acetylation was found [39]. The decline in
SIRT1, together with p53 deacetylation status, could
reflect decreased synthesis of this deacetylase, but
increased activity mediated by resveratrol [40–42] or
by crossregulation with the AMPK/LKB pathway [34,
43, 44].
Canto´ and Auwerx [45] demonstrated that activa-
tion of AMPK stimulated the functional activity of
SIRT1 by increasing the intracellular concentration of
NAD+. Interestingly, SIRT1 was able to deacetylate
LKB1 kinase, which subsequently increased its activ-
ity [46]. Because LKB1 is an upstream activator of
AMPK, this signaling pathway stimulates the activa-
tion of AMPK. This positive feedback loop between
SIRT1 and AMPK can also potentiate the function of
the other AMPK-activated signaling pathways [47].
In the current study, the surprising resveratrol-induced
decline in SIRT1 levels is consistent with AMPK/LKB
activation.
The AMPK and SIRT1 signaling pathways are
highly conserved energy sensors of increased lev-
els of AMP and NAD+, respectively, and AMPK
signaling is involved in the regulation of energy
metabolic homeostasis [48]. In line with this, resver-
atrol also normalized mitochondrial function and
enhanced mitochondrial biogenesis in the spinal cord
of SOD1G93A amyotrophic lateral sclerosis mice [49].
The majority of the pathways mentioned previously are
involved in mitochondrial function, and in this partic-
ular organelle, the APP/PS1 life-long treatment with
resveratrol induced an increase in complex IV. MCIV
is considered a marker of mitochondrial functional-
ity [4, 5], which in turn is known to be decreased in
AD. In our study, resveratrol increased MCIV, because
this action can be taken in account for delineating
the neuroprotective role of resveratrol in APP/PS1
mice.
In conclusion, this study supports some unexplored
pathways responsible for the neuroprotective effects of
resveratrol in APP/PS1 mice, namely, the equilibrium
among SIRT1 and AMPK signaling, mitochondrial sta-
tus, and inflammatory changes. In addition to other
reports [26, 50], our findings indicate that the onset of
this neurodegenerative disease may be delayed or mit-
igated employing dietary resveratrol, which is able to
protect against Aplaque formation and cognitive loss.
Further studies need to be conducted to elucidate the
precise regulatory mechanisms that can be modulated
by resveratrol in the APP/PS1 mouse model.
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